Edgewise Therapeutics (EWTX) risk factors, FY2024 10-K

Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History

1. 01We have a limited operating history, some of our product candidates are early in development and we have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and future viability
2. 02We have not generated any revenue to date, have incurred significant net losses since our inception, and expect to continue to incur significant net losses for the foreseeable future
3. 03Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the discovery, development and commercialization of our product candidates, if approved
4. 04We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts
5. 05A change in the outcome of any of these or other factors with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate
6. 06Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop our product candidates
7. 07Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
8. 08assets to secure future indebtedness. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan
9. 09Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited
10. 10Changes in tax laws could have a material adverse effect on our business, cash flow, results of operations or financial conditions
11. 11Market conditions and changing circumstances, some of which may be beyond our control, could impair our ability to access our existing cash, cash equivalents and investments and to timely pay key vendors and others
12. 12Our operations and financial results could be adversely impacted by public health pandemics, such as COVID-19 and other related outbreaks in the United States and the rest of the world
13. 13Any continued and prolonged public health crisis, such as the COVID-19 pandemic, could have a material negative impact on our business, financial condition and operating results

Risks Related to the Discovery, Development and Commercialization of Our Product Candidates

1. 14We are substantially dependent on the success of our lead product candidates, sevasemten and EDG-7500. If we are unable to complete further development of, obtain approval for and commercialize sevasemten or EDG-7500 for one or more indications in a timely manner, our business will be harmed
2. 15The outcome of preclinical testing and clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities
3. 16If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented
4. 17We have limited resources and are currently focusing the majority of our efforts on developing sevasemten and EDG-7500 for particular indications. As a result, we may fail to capitalize on other indications or product candidates that may ultimately have proven to be more profitable
5. 18We face significant competition and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the products we develop, our commercial opportunities will be negatively impacted
6. 19Interim, topline and preliminary data from our clinical trials that we announce or publish may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data
7. 20We may not be successful in our efforts to develop a proprietary drug discovery platform to build a pipeline of product candidates
8. 21We may develop sevasemten and potentially other programs in combination with other therapies, which would expose us to additional risks
9. 22Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
10. 23Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success
11. 24If any of our product candidates are approved but do not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively impacted
12. 25We may not be successful in augmenting our product pipeline through acquisitions and in-licenses
13. 26Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations

Risks Related to Regulatory Approval and Other Legal Compliance Matters

1. 27specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may significantly limit the size of the market for the drug and affect reimbursement by third-party payors
2. 28The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction
3. 29Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
4. 30The regulatory approval processes for product candidates that target rare diseases, including Duchenne, Becker and LGMD are uncertain
5. 31Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight
6. 32We may not be able to obtain orphan drug designation or obtain or maintain orphan drug exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA, EMA or other comparable foreign regulatory authorities, from approving competing products
7. 33We may face difficulties from changes to current regulations and future legislation
8. 34Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
9. 35If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business

Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business

1. 36Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees
2. 37If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval
3. 38In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth
4. 39actual or perceived security breach or incident. We also rely on third parties to manufacture our product candidates, and for other purposes, and similar events relating to their infrastructure and systems could also have a material adverse effect on our business
5. 40Our operations are vulnerable to interruption by fire, earthquakes, power loss, telecommunications failure, terrorist activity, pandemics and other events beyond our control, which could harm our business
6. 41Our business may become subject to economic, political, regulatory and other risks associated with international operations directly or indirectly. A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business
7. 42Inflation in the global economy could negatively impact our business and results of operations

Risks Related to Our Intellectual Property

1. 43Our success depends on our ability to protect our intellectual property and our proprietary technologies
2. 44If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected
3. 45Intellectual property rights do not necessarily address all potential threats to our competitive advantage
4. 46Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts
5. 47We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses
6. 48We may be involved in lawsuits to protect or enforce our patents or any licensor’s patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents or any licensor’s patents could be found invalid or unenforceable if challenged in court
7. 49In addition, if the breadth or strength of protection provided by our patents and patent applications or the patents and patent applications of any licensor is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates
8. 50In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology
9. 51Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline
10. 52Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party
11. 53Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
12. 54We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
13. 55Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
14. 56If we do not obtain patent term extension for our product candidates, our business may be materially harmed
15. 57We may not be able to protect our intellectual property rights throughout the world
16. 58Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
17. 59If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
18. 60If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
19. 61We may be subject to claims that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets
20. 62We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers
21. 63Our rights to develop and commercialize our technology and product candidates may be subject, in part, to the terms and conditions of licenses granted to us by others
22. 64If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with any licensors, we could lose license rights that are important to our business
23. 65The patent protection and patent prosecution for some of our product candidates may be dependent on third parties
24. 66may still be adversely affected or prejudiced by actions or inactions of our licensees, any licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution

Risks Related to Our Dependence on Third Parties

1. 67We rely, and expect to continue to rely, on third parties to conduct our clinical trials and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies, which may harm our business
2. 68Our reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
3. 69If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks
4. 70If we decide to establish collaborations, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans
5. 71our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business
6. 72We may enter into collaborations with third parties for the development and commercialization of product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates

Risks Related to the Securities Markets and Ownership of Our Common Stock

1. 73An active, liquid and orderly trading market may not continue to be developed or sustained for our common stock and as a result it may be difficult for you to sell your shares of our common stock
2. 74The price of our stock has been and may continue to be volatile, and you could lose all or part of your investment
3. 75Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance
4. 76Our affiliated principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
5. 77Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall
6. 78If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline
7. 79We incur significantly increased costs and devote substantial management time as a result of operating as a public company. Additionally, if we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired
8. 80Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
9. 81We may be subject to securities litigation, which is expensive and could divert management attention
10. 82We do not intend to pay dividends on our common stock in the foreseeable future, so any returns will be limited to the value of our common stock
11. 83Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock
12. 84Our amended and restated bylaws further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act